Abstract
The mammalian target of rapamycin (mTOR) plays an important role in cell growth. Dysfunction of mTOR has been linked to many human diseases, such as cancers, obesity, diabetes, cardiovascular diseases and neurological disorders. Currently, the mTOR inhibitor rapamycin and its analogs have been vigorously evaluated and developed as anticancer drugs. Here, we will review the most recent patents and patent applications relating to mTOR pathway. Moreover, we will discuss the patents and patent applications on the treatment of mTOR-associated metabolic diseases and cancers.
Keywords: mTOR, mTORC1, mTORC2, rapamycin, Akt/PKB, S6K, 4EBP1, TSC1/TSC2, Rheb, cancer
Related Books
Angelman Syndrome: Communication, Educational and Related Considerations
Consanguinity - Its Impact, Consequences and Management
Down Syndrome Children - An Update
Epigenetics of Lifestyle
Frontiers in RNAi
Anthropology: Current and Future Developments
Anthropology: Current and Future Developments
Introduction to Molecular Genomics
Next-Generation Sequencing and Sequence Data Analysis
Sperm-Mediated Gene Transfer: Concepts and Controversies
43